{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:39:22Z","timestamp":1784774362042,"version":"3.55.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.pharmthera.2006.03.005","type":"journal-article","created":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T13:09:41Z","timestamp":1146661781000},"page":"57-70","source":"Crossref","is-referenced-by-count":38,"title":["B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target"],"prefix":"10.1016","volume":"112","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2006.03.005_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(98)80172-6","article-title":"Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling","volume":"10","author":"Abraham","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib2","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.4049\/jimmunol.170.9.4497","article-title":"Determinants of human B cell migration across brain endothelial cells","volume":"170","author":"Alter","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2003.12.004","article-title":"The Guillain-Barr\u00e9 syndrome: a true case of molecular mimicry","volume":"25","author":"Ang","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/brain\/awg118","article-title":"B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas","volume":"126","author":"Anthony","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.61.10.922","article-title":"Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)","volume":"61","author":"Arzoo","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib6","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.4049\/jimmunol.174.7.4034","article-title":"Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage","volume":"174","author":"Avery","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib7","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib8","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.163.9.5133","article-title":"B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions","volume":"163","author":"Baranzini","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib9","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.4049\/jimmunol.167.10.5669","article-title":"Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state","volume":"167","author":"Bar-Or","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1212\/WNL.46.6.1633","article-title":"Interferon-\u03b21b treatment decreases tumor necrosis factor-\u03b1 and increases interleukin-6 production in multiple sclerosis","volume":"46","author":"Brod","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpneuro0033","article-title":"Autoimmune Channelopathies","volume":"1","author":"Buckley","year":"2005","journal-title":"Nature Clin Pract Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1385\/CRIAI:20:1:155","article-title":"The Lambert-Eaton myasthenic syndrome","volume":"20","author":"Carpentier","year":"2001","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI115007","article-title":"New roles for rheumatoid factor","volume":"87","author":"Carson","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/brain\/124.11.2169","article-title":"Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis","volume":"124","author":"Cepok","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/awh486","article-title":"Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis","volume":"128","author":"Cepok","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","article-title":"A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus","volume":"189","author":"Chan","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2249.2005.02653.x","article-title":"Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients","volume":"139","author":"Chan","year":"2005","journal-title":"Clinic and Experiment Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib20","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1212\/WNL.43.10.1911","article-title":"Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barr\u00e9 syndrome: clinical and immunohistochemical studies","volume":"43","author":"Chiba","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib22","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.4049\/jimmunol.164.5.2782","article-title":"Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients","volume":"164","author":"Colombo","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib23","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.4049\/jimmunol.162.10.5695","article-title":"B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo","volume":"162","author":"Constant","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2990.1989.tb01231.x","article-title":"Immunocytochemical localization of the terminal complement complex in multiple sclerosis","volume":"15","author":"Compston","year":"1989","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib25","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1073\/pnas.0402455101","article-title":"Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis","volume":"101","author":"Corcione","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(00)00409-4","article-title":"B cells and antibodies in CNS demyelinating disease","volume":"112","author":"Cross","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00415-004-0323-5","article-title":"Immune mediated neuropathies: an update on therapeutic strategies","volume":"251","author":"Czaplinski","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib28","series-title":"Clinical Immunology","first-page":"78.1","article-title":"Autoimmune peripheral neuropathies","author":"Dalakas","year":"2001"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib29","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archneur.1980.00500590061010","article-title":"Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy","volume":"37","author":"Dalakas","year":"1980","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ana.410390402","article-title":"Autoimmune ataxic Neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens?","volume":"39","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.55.10.1531","article-title":"The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome","volume":"55","author":"Dalakas","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff-person syndrome: quantification, specificity and intrathecal synthesis of GAD65 antibodies","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00005792-199203000-00001","article-title":"Anti-Hu-associated paraneoplastic encephalomyelitis\/sensory neuropathy: a clinical study of 71 patients","volume":"71","author":"Dalmau","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib36","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic syndromes involving the nervous system","volume":"349","author":"Darnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib37","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1212\/WNL.45.12.2173","article-title":"Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon beta-1b","volume":"45","author":"Dayal","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib38","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/eji.1830191221","article-title":"Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4","volume":"19","author":"Daynes","year":"1989","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.410440209","article-title":"Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome","volume":"44","author":"Dinkel","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib40","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib42","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.172.6.3422","article-title":"Distinct profiles of human B cell effector cytokines: a role in immune regulation?","volume":"172","author":"Duddy","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2567.1999.00772.x","article-title":"Do self-perpetuating B lymphocytes drive human autoimmune disease?","volume":"97","author":"Edwards","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib44","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib45","first-page":"1830","article-title":"Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis","volume":"24","author":"Eisenstein","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0046-8177(86)80180-0","article-title":"Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies","volume":"17","author":"Engel","year":"1986","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib47","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s00415-002-0800-7","article-title":"Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study","volume":"249","author":"Fassas","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib48","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/5532","article-title":"Identification of autoantibodies associated with myelin damage in multiple sclerosis","volume":"5","author":"Genain","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib50","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1172\/JCI119455","article-title":"Increased, C.D80+ B cells in active multiple sclerosis and reversal by interferon \u03b2-1b therapy","volume":"99","author":"Gen\u00e7","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","article-title":"Immunotherapy in autoimmune neuromuscular disorders","volume":"2","author":"Gold","year":"2003","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib52","series-title":"Kuby immunology","author":"Goldsby","year":"2000"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-dose (7.5\u00a0mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis","volume":"37","author":"Goodkin","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib54","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"24","author":"Graus","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: ongoing and future clinical development","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.1030","article-title":"Neuroimmunophilins: novel neuroprotective and neuroregenerative targets","volume":"50","author":"Guo","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(97)12308-X","article-title":"The Guillain-Barr\u00e9 syndrome","volume":"352","author":"Hahn","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib60","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","article-title":"Phenotypic variants of autoimmune peripheral nerve hyperexcitability","volume":"125","author":"Hart","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib61","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneur.61.6.938","article-title":"Stiff-person syndrome following West Nile fever","volume":"61","author":"Hassin-Baer","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib63","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0165-5728(88)90101-4","article-title":"Immune reactive C3d on the surface of myelin sheaths in neuropathy","volume":"18","author":"Hays","year":"1988","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-41139","article-title":"Basic principles of immunotherapy for neurologic diseases","volume":"23","author":"Hohlfeld","year":"2003","journal-title":"Semin Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib65","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/WNL.47.4.889","article-title":"Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years","volume":"47","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib66","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0896-6273(00)80900-9","article-title":"Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability","volume":"25","author":"Jensen","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ajh.10079","article-title":"EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency","volume":"69","author":"Kasamon","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib70","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","article-title":"Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange","volume":"366","author":"Keegan","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","article-title":"Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system","volume":"30","author":"Kieseier","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib73","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4049\/jimmunol.161.2.692","article-title":"Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells","volume":"161","author":"Knopf","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2003-41131","article-title":"Antibody-associated polyneuropathy syndromes: principles and treatment","volume":"23","author":"Kornberg","year":"2003","journal-title":"Semin Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-200464060-00003","article-title":"Guillain-Barr\u00e9 syndrome: epidemiology, pathophysiology and management","volume":"64","author":"Kuwabara","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0079-6123(08)61957-3","article-title":"Antibodies to glycoconjugates in neuropathy and motor neuron disease","volume":"101","author":"Latov","year":"1994","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib78","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib79","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib80","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib81","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1086\/344734","article-title":"Cross-reactivity between immunodominant human T lymphotropic virus type I tax and neurons: implications for molecular mimicry","volume":"186","author":"Levin","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1023912425610","article-title":"Myelopathy from Waldenstrom's macroglobulinemia: improvement after rituximab therapy","volume":"63","author":"Liberato","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib83","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(96)10310-X","article-title":"Mycophenolate Mofetil","volume":"348","author":"Lipsky","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib84","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ni0901-764","article-title":"Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity","volume":"2","author":"Lipsky","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib85","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib86","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.coph.2004.02.009","article-title":"The role of the BAFF\/APRIL system in B cell homeostasis and lymphoid cancers","volume":"4","author":"Mackay","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib88","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0165-5728(00)00223-X","article-title":"Restricted immune responses lead to CNS demyelination and axonal damage","volume":"107","author":"Mancardi","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib89","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2249.1990.tb05121.x","article-title":"B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiple sclerosis","volume":"79","author":"Mix","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib91","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of Rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/14737175.4.1.17","article-title":"Mitoxantrone (Novantrone) in multiple sclerosis: new insights","volume":"4","author":"Neuhaus","year":"2004","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0165-5728(01)00266-1","article-title":"Multifocal motor neuropathy","volume":"115","author":"Nobile-Orazio","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib94","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00019052-200410000-00010","article-title":"IgM paraproteinaemic neuropathies","volume":"17","author":"Nobile-Orazio","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib95","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O","article-title":"Axonal Guillain-Barr\u00e9 syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan","volume":"48","author":"Ogawara","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib96","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.4049\/jimmunol.171.5.2725","article-title":"Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid","volume":"171","author":"Owens","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib97","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","article-title":"Paraneoplastic cerebellar degeneration: I. A clinical analysis of 55 anti-Yo antibody positive patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib98","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib99","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.20125","article-title":"CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity","volume":"19","author":"Pranzatelli","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib101","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI3568","article-title":"Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis","volume":"102","author":"Qin","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib102","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.LAB.0000077008.24259.0D","article-title":"Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis","volume":"83","author":"Qin","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib103","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/(SICI)1097-4598(199907)22:7<800::AID-MUS2>3.0.CO;2-F","article-title":"Autoantibodies associated with peripheral neuropathy","volume":"22","author":"Quarles","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib104","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1749-6632.1998.tb10931.x","article-title":"Immune regulation and myasthenia gravis","volume":"841","author":"Ragheb","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/1531-8249(199908)46:2<144::AID-ANA3>3.0.CO;2-K","article-title":"Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation","volume":"46","author":"Raine","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib106","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.4049\/jimmunol.175.11.7755","article-title":"Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients","volume":"75","author":"Raju","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib107","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib108","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/122.11.2047","article-title":"Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study","volume":"122","author":"Reindl","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.4049\/jimmunol.173.1.649","article-title":"Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis","volume":"173","author":"Ritchie","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib111","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.coi.2004.07.009","article-title":"Neuroimmunology of the paraneoplastic neurological degenerations","volume":"16","author":"Roberts","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.173.2.487","article-title":"Efficient and selective presentation of antigen\u2013antibody complexes by rheumatoid factor B cells","volume":"173","author":"Roosnek","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib113","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199805283382207","article-title":"Neuropathies associated with paraproteinemia","volume":"338","author":"Ropper","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib114","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.1288","article-title":"Molecular and clinical diversity in Paraneoplastic immunity to Ma proteins","volume":"50","author":"Rosenfeld","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/jnnp.52.5.559","article-title":"Randomised double blind controlled trial of cyclosporin in multiple sclerosis","volume":"52","author":"Rudge","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib116","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1212\/01.WNL.0000145706.04340.25","article-title":"Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg","volume":"63","author":"Ruegg","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib117","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib119","series-title":"Immunology, immunopathology and immunity","author":"Sell","year":"2001"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","article-title":"From T to B and back again: positive feedback in systemic autoimmune disease","volume":"1","author":"Shlomchik","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib122","series-title":"Clinical immunology","first-page":"92","article-title":"Principles of immunotherapy","author":"Smith","year":"1998"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib123","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJM199005313222202","article-title":"Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome","volume":"322","author":"Solimena","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib124","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14728222.8.3.177","article-title":"Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders","volume":"8","author":"Stohl","year":"2004","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1750-3639.1998.tb00194.x","article-title":"Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology","volume":"8","author":"Storch","year":"1998","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib126","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archneur.62.10.1620","article-title":"Clinical stabilization and effective bB-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing\u2013remitting multiple sclerosis","volume":"62","author":"Stuve","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib127","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/1521-4141(200207)32:7<1939::AID-IMMU1939>3.0.CO;2-S","article-title":"A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination","volume":"32","author":"Svensson","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib128","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib129","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1096\/fj.01-1023fje","article-title":"Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease","volume":"16","author":"Ure","year":"2002","journal-title":"FASEB"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1023\/A:1006682225181","article-title":"Stem cell transplantation in experimental models of autoimmune disease","volume":"20","author":"van Bekkum","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib131","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI22833","article-title":"Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS","volume":"115","author":"Villar","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","article-title":"Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis","volume":"18","author":"Vincent","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib133","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission","volume":"267","author":"Vincent","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib134","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1474-4422(02)00135-7","article-title":"Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy","volume":"1","author":"Voltz","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib136","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1046\/j.1365-2141.2000.02086.x","article-title":"The polyneuropathy associated with Waldenstrom's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab","volume":"109","author":"Weide","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib137","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0889-857X(03)00109-1","article-title":"B-cell biology","volume":"30","author":"Weinstein","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib138","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMcibr035136","article-title":"Molecular mimicry in multiple sclerosis","volume":"349","author":"Wekerle","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib139","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1073\/pnas.031567598","article-title":"Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis","volume":"98","author":"Williamson","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib140","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib141","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2741\/1267","article-title":"Neuromyelitis optica: current concepts","volume":"9","author":"Wingerchuk","year":"2004","journal-title":"Front Biosci"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib142","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1172\/JCI119622","article-title":"Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes","volume":"100","author":"Wucherpfennig","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib143","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib144","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","article-title":"Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients","volume":"47","author":"Yan","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E","article-title":"CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity","volume":"49","author":"Yu","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib146","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barr\u00e9 syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmthera.2006.03.005_bib147","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725806000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725806000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:02:45Z","timestamp":1683450165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725806000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":144,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0163725806000428"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2006.03.005","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}